ZMIZ1

Across TCGA pan-cancer cohorts, ZMIZ1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZMIZ1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZMIZ1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZMIZ1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where ZMIZ1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.785	0.123	.009	25	view →
PDAC	OS	Median	III,IV	0.370	0.816	.009	6	view →
HNSC	DFS	Median	All	0.842	0.703	.016	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZMIZ1–CCRCC (OS)

Open the CCRCC breakdown →